Janux Therapeutics
Developing unique immunotherapies that generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 Valuation: €0.0 187.0x EV/Revenue -20.6x EV/EBITDA | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | N/A | $300m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 137 % | (6 %) | 31 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (905 %) | (779 %) | (879 %) | (914 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (898 %) | (732 %) | (721 %) | (652 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 721 % | 621 % | 679 % | 646 % |
Source: Company filings or news article
Related Content
Janux Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies designed to treat cancer. The company specializes in creating tumor-activated immunotherapies that stimulate the immune system within the tumor microenvironment, aiming to attack and kill tumors without harming healthy tissue. Janux employs its proprietary platform masking technology to engineer novel drug candidates that address the traditional limitations of T cell engagers, such as toxicity and efficacy issues. The primary clients are cancer patients, and the company operates within the biopharmaceutical market. Janux's business model revolves around advancing its drug candidates through clinical trials, with the goal of obtaining regulatory approval and subsequently commercializing these therapies. Revenue is generated through partnerships, licensing agreements, and eventually, the sale of approved therapies. Currently, Janux is actively recruiting for its Phase 1 clinical trial, ENGAGER PSMA 01, to evaluate the safety and efficacy of its lead candidate, JANX007, in patients with metastatic prostate cancer.
Keywords: immunotherapy, cancer treatment, tumor-activated, T cell engagers, clinical trials, biotechnology, drug development, platform masking technology, metastatic prostate cancer, JANX007.